{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:21Z","timestamp":1740144201408,"version":"3.37.3"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"e National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81672974"],"award-info":[{"award-number":["81672974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR201702200659"],"award-info":[{"award-number":["ZR201702200659"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Reversible posterior leukoencephalopathy syndrome (RPLS) is characterized by rapidly progressive hypertension, headache, and disturbance of consciousness. Moreover, RPLS is rarely reported after apatinib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We present a case of RPLS induced by apatinib in this report. The patient had dizziness and bilateral lower limb weakness after apatinib use for 12 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis and interventions:<\/jats:title>\n            <jats:p>Cranial T2-weighted magnetic resonance imaging (MRI) revealed symmetrical increased signal intensity in bilateral areas of the basal ganglia, radiation crown, frontal lobe, parietal lobe, and occipital lobe, which was suggestive of RPLS. The patient discontinued apatinib use and was administered dexamethasone, mannitol, and antihypertensive drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient's blood pressure returned to normal and neurological symptoms improved after 3 days of discontinuation of apatinib use. Moreover, brain MRI showed complete resolution of previous changes after 44 days of discontinuation of apatinib use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Increased blood pressure may damage the normal blood-brain barrier, resulting in the extravasation of the fluid into the brain parenchyma. Hypertension is a significant cause of RPLS. It is important to strictly monitor blood pressure during apatinib treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017787","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T13:14:09Z","timestamp":1573737249000},"page":"e17787","source":"Crossref","is-referenced-by-count":4,"title":["Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult"],"prefix":"10.1097","volume":"98","author":[{"given":"Yajuan","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Radiotherapy,The First Affiliated Hospital of Shandong First Medical University, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy,The First Affiliated Hospital of Shandong First Medical University, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy,The First Affiliated Hospital of Shandong First Medical University, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy,The First Affiliated Hospital of Shandong First Medical University, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy,The First Affiliated Hospital of Shandong First Medical University, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Liu","sequence":"additional","affiliation":[{"name":"Weifang Medical University, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leuko-encephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N End J Med"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11912-008-0013-z","article-title":"Reversible posterior leukoencephalopathy syndrome in cancer","volume":"10","author":"Vaughn","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0031-1277990","article-title":"Posterior reversible encephalopathy syndrome: a review","volume":"31","author":"Feske","year":"2011","journal-title":"Semin Neurol"},{"issue":"(suppl 1)","key":"R4-20230915","first-page":"28","article-title":"Gastric Cancer Working Group report","volume":"40","author":"Sasako","year":"2010","journal-title":"Jan J Clin Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2016.01.014","article-title":"Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer","volume":"372","author":"Roviello","year":"2016","journal-title":"Cancer Lett"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.2147\/OTT.S166605","article-title":"reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review","volume":"11","author":"Li","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","article-title":"Posterior reversible encephalopathy syndrome induced by anti-VEGF agents","volume":"6","author":"Tlemsani","year":"2011","journal-title":"Target Oncol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/annonc\/mdx383.013","article-title":"Clinical features and outcomes of reversible posterior encephalopathy syndrome following bevacizumab treatment","volume":"28","author":"Iwamoto","year":"2017","journal-title":"Ann Oncol"},{"key":"R9-20230915","first-page":"952624","article-title":"Reversible posterior encephalopathy syndrome secondary to sunitinib","volume":"2014","author":"Costa","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clcc.2013.12.003","article-title":"Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors","volume":"13","author":"Myint","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clgc.2013.08.008","article-title":"Reversible posterior leukoencephalopathy syndrome induced by axitinib","volume":"12","author":"Levy","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13691-017-0306-x","article-title":"Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma","volume":"6","author":"Nakamura","year":"2017","journal-title":"Int Canc Conf J"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s10637-014-0113-6","article-title":"Atypical reversible posterior leukoencephalopathy syndrome(RPLS) induced by cediranib in a patient with metastatic rectal cancer","volume":"32","author":"Kim","year":"2014","journal-title":"Invest New Drugs"},{"key":"R14-20230915","first-page":"281","article-title":"Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: a report of two cases","volume":"7","author":"Furubayashi","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000443970","article-title":"Posterior reversible encephalopathy syndrome associated with sorafenib and successful retreatment","volume":"100","author":"Laruelle","year":"2018","journal-title":"Urol Int"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s12032-009-9378-6","article-title":"Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma","volume":"27","author":"Dogan","year":"2010","journal-title":"Med Oncol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000350742","article-title":"Posterior reversible leukoencephalopathy syndrome associated with pazopanib","volume":"6","author":"Foerster","year":"2013","journal-title":"Case Rep Oncol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/1471-2407-12-489","article-title":"Reversible posterior leukoencephalopathy syndrome induced by pazopanib","volume":"12","author":"Chelis","year":"2012","journal-title":"BMC Cancer"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.clgc.2016.08.005","article-title":"Posterior reversible encephalopathy syndrome with concurrent nephrotic syndrome in a patient treated with pazopanib for metastatic renal cell carcinoma: case report and review of the literature","volume":"15","author":"Miaris","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jcpt.12031","article-title":"Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma","volume":"38","author":"Asaithambi","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"pii: bcr-2016-218221","DOI":"10.1136\/bcr-2016-218221","article-title":"Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage","volume":"17","author":"Miller-Patterson","year":"2017","journal-title":"BMJ Case Rep"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Jin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.2147\/OTT.S157466","article-title":"Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis","volume":"11","author":"Chen","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.20147","article-title":"Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies","volume":"77","author":"Tam","year":"2004","journal-title":"Am J Hematol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.carj.2016.08.005","article-title":"Posterior reversible encephalopathy syndrome: a review","volume":"68","author":"Shankar","year":"2017","journal-title":"Can Assoc Radiol J"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.sult.2013.09.007","article-title":"Posterior reversible encephalopathy syndrome","volume":"35","author":"Rykken","year":"2014","journal-title":"Semin Ultrasound CT MR"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:24:29Z","timestamp":1694816669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017787"}},"subtitle":["A case report and a review of the literature"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":26,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017787","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}